[Comparison of pars plana vitrectomy with ILM peeling and intravitreal triamcinolone in diffuse diabetic macular oedema]
- PMID: 20221984
- DOI: 10.1055/s-0028-1109884
[Comparison of pars plana vitrectomy with ILM peeling and intravitreal triamcinolone in diffuse diabetic macular oedema]
Abstract
Background: Visual outcome and anatomic results in patients with diffuse diabetic macular oedema (DDME) were evaluated after vitrectomy with internal limiting membrane (ILM) peeling versus intravitreal triamcinolone acetonide (TA).
Materials and methods: A prospective, non-randomised pilot study included 41 eyes (35 patients) with clinically significant DDME. In 24 eyes (group A) we performed pars plana vitrectomy with ILM peeling. Seventeen eyes (group B) received an injection of 10 mg TA. Best corrected visual acuity and central macular thickness (measured with OCT) were determined preoperatively as well as 1 and 4 months postoperatively.
Results: In group A, OCT showed a macular thickness of 403 +/- 142 microm preoperatively. Best corrected visual acuity was 0.24 +/- 0.18. One month after surgery, macular thickness decreased to 311 +/- 62 microm (p = 0.06 ns) and visual acuity was 0.17 +/- 0.14 (ns). Four months after surgery, macular thickness remained significantly lower compared with preoperative values, at 307 +/- 161 microm (p = 0.012). There was a tendency towards a higher visual acuity of 0.30 +/- 0.26 (p = 0.32 ns). Before TA injection, macular thickness in group B was 551 +/- 180 microm and visual acuity was 0.19 +/- 0.14. One month after TA, macular thickness decreased to 242 +/- 82 (p = 0.001) microm while visual acuity increased to 0.31 +/- 0.21 (p = 0.005). At 4 months follow-up, group B showed recurrence of macular oedema. Compared with the preoperative findings macular thickness was significantly lower (368 +/- 159 microm; p = 0,001). Best corrected visual acuity after 4 months was 0.27 +/- 0.17 and did not differ significantly from the preoperative visual acuity (p = 0.033 ns).
Conclusions: Intravitreal TA as a single treatment reduces the extent of DDME within a short time after surgery. These promising results may not be stable during long-term follow-up, necessitating in many cases a re-injection of TA. Macular oedema reduction after vitrectomy with ILM peeling, however, remains stable for more than 4 months and, therefore, offers more permanent results. However, none of these treatments facilitated a significant visual acuity restoration 4 months postoperatively.
Georg Thieme Verlag KG Stuttgart, New York.
Similar articles
-
Pars plana vitrectomy with internal limiting membrane peeling compared with intravitreal triamcinolone injection in the treatment of diabetic macular edema.Ophthalmologica. 2009;223(1):17-23. doi: 10.1159/000161878. Epub 2008 Oct 13. Ophthalmologica. 2009. PMID: 18849632
-
[Triamcinolone in the treatment of the diabetic macular edema--one-year results].Cesk Slov Oftalmol. 2008 Jul;64(4):149-52. Cesk Slov Oftalmol. 2008. PMID: 18780654 Clinical Trial. Czech.
-
[Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].Klin Monbl Augenheilkd. 2011 Oct;228(10):910-4. doi: 10.1055/s-0029-1245965. Epub 2011 Oct 13. Klin Monbl Augenheilkd. 2011. PMID: 21997827 German.
-
ILM peeling in nontractional diabetic macular edema: review and metanalysis.Int Ophthalmol. 2018 Dec;38(6):2709-2714. doi: 10.1007/s10792-017-0761-6. Epub 2017 Oct 31. Int Ophthalmol. 2018. PMID: 29090356 Review.
-
Treatment options for diffuse diabetic macular edema.Eur J Ophthalmol. 2011;21 Suppl 6:S45-50. doi: 10.5301/EJO.2010.6054. Eur J Ophthalmol. 2011. PMID: 23264328 Review.
Cited by
-
Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema.Clin Ophthalmol. 2012;6:2063-8. doi: 10.2147/OPTH.S36609. Epub 2012 Dec 11. Clin Ophthalmol. 2012. PMID: 23271887 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous